New book by Larry Connors Click here Improve your trading - See how
The Newest and Revolutionary Technology for Increasing Investor Visability.
REAL Awareness for REAL Companies.
Click below for a full demonstration.
http://newmediaadvisors.info/newmedia.swf
Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at www.Standoutstocks.com
Feb 19, 2009 -- Depomed, Inc. (NASDAQ: DEPO | Quote | Chart | News | PowerRating) announced today that it will release fourth quarter and year-end results for 2008 after the market closes on Thursday, March 5, 2009. The company will host a conference call beginning at 5:00 p.m. ET, 2:00 p.m. PT to discuss its results.
The conference call will be available via a live webcast on the investor relations section of Depomed's website. Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.
About Depomed
Depomed, Inc. is a specialty pharmaceutical company with two approved products on the market and other product candidates in its pipeline. The company utilizes its proven, proprietary AcuForm(TM) drug delivery technology to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract. Benefits of AcuForm-enhanced pharmaceuticals include the convenience of once-daily administration, improved treatment tolerability and enhanced compliance and efficacy. GLUMETZA(R) (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. Proquin(R) XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is being marketed in the United States within the urology, Ob/Gyn and long-term care specialties by Watson Pharmaceuticals. Product candidate DM-1796 is in clinical development for the treatment of neuropathic pain and has been licensed to Solvay Pharmaceuticals. Product candidate DM-5689 is in clinical development for menopausal hot flashes.
Feb 19, 2009 -- DivX, Inc. (NASDAQ: DIVX), a digital media company, announced today that it will issue its earnings release for the fourth quarter and fiscal 2008 after the market close on Monday, March 9, 2009.
DivX management will host a conference call and simultaneous audio webcast to discuss its fourth quarter and fiscal 2008 results on March 9, 2009 at 1:30 p.m. Pacific Time or 4:30 p.m. Eastern Time. To participate in the call, please dial (877) 723-9522 or outside the U.S. (719) 325-4839 to access the conference call at least five minutes prior to the start time. A live audio webcast will be available on the Events and Presentations page.
In addition, an audio replay of the call will be available between 7:30 p.m. ET March 9, 2009 and 11:59 p.m. ET March 16, 2009 by calling (888) 203-1112, or (719) 457-0820, with passcode 1080246.
About DivX, Inc.
DivX, Inc. is a digital media company that enables consumers to enjoy a high-quality video experience across any kind of device. DivX creates, distributes and licenses digital video technologies that span the "three screens" comprising today's consumer media environment--the PC, the television and mobile devices. Over 100 million DivX Certified devices have shipped into the market from leading consumer electronics manufacturers. DivX also offers content providers and publishers a complete solution for the distribution of secure, high-quality digital video content. Driven by a globally recognized brand and a passionate community of hundreds of millions of consumers, DivX is simplifying the video experience to enable the digital home.
Feb 19, 2009 -- MiddleBrook Pharmaceuticals, Inc. (NASDAQ: MBRK | Quote | Chart | News | PowerRating) is scheduled to announce its financial results for the 2008 fourth quarter and full year on Thursday, March 5, 2009, before the market opens. At 9:00 a.m. (ET) on that day, MiddleBrook management will conduct a conference call to review results for the 2008 fourth quarter and full year.
To listen live to the call, dial 1-800-813-8504 or 1-660-422-4526. A replay of the call will be available starting at approximately 11 a.m. on March 5 through 5 p.m. on March 12, 2009. To listen to the replay, dial 1-800-642-1687 or 1-706-645-9291, and enter the conference ID # 86529116.
A live audio webcast of the conference call also will be available by going to the Investor Relations section of MiddleBrook's web site, www.middlebrookpharma.com. A replay of the webcast will be available starting at approximately 11 a.m. on March 5 through 5 p.m. on April 3, 2009.
About MiddleBrook Pharmaceuticals:
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK | Quote | Chart | News | PowerRating) is a pharmaceutical company focused on developing and commercializing anti-infective products that fulfill unmet medical needs. We have developed a proprietary delivery technology called PULSYS(R), which enables delivery in rapid bursts, or pulsatile delivery, of certain drugs. We are currently developing a portfolio of anti-infective products utilizing our PULSYS(R) technology. Our near-term corporate strategy is to improve dosing regimens and/or reduce frequency of dosing for antibiotics that have been used and trusted by physicians and patients for decades which we believe will result in improved patient dosing convenience and compliance. MiddleBrook currently markets KEFLEX(R), the immediate-release brand of cephalexin, and will begin promoting MOXATAG(TM) - the first and only FDA-approved once-daily amoxicillin - to health care professionals nationwide on March 16, 2009.
Feb 19, 2009 -- Universal Detection Technology (OTCBB: UNDT), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats and provider of counter-terrorism consulting and training services, issued an analysis of the funds allocated to the Department of Homeland Security (DHS) as part of President Obama's $787 Billion Stimulus Plan. The DHS is set to receive a $2.8 billion budget boost as part of the plan.
The largest single item is $1 billion for the Transportation Security Administration (TSA) for technologies and tasks, including checked baggage explosive detection systems. These are generally systems that use X-rays and digital three-dimensional scanning. The U.S. Customs and Border Protection (CBP) also will receive $420 million to help pay for construction and renovation of land border ports of entry. Many of those border entry and exit points are being expanded and reconfigured in part to make room for sophisticated scanners and identification checking equipment.
The bill also directs $300 million into state and local grant programs for port security, rail security, and mass transit security. A large chunk of that grant money is likely to pay for IT-related systems, such as access control, camera monitoring, perimeter alarm systems, underwater surveillance and tunnel surveillance systems.
"We have been closely monitoring President Obama's Stimulus plan and we are prepared to take advantage of the opportunities it offers for companies in the Homeland Security sector," said Mr. Jacques Tizabi, UNDT's Chief Executive Officer.
About Universal Detection Technology
Universal Detection Technology is a developer of monitoring technologies, including bioterrorism detection devices. The Company on its own and with development partners is positioned to capitalize on opportunities related to Homeland Security. For example, the Company, in cooperation with NASA, has developed a bacterial spore detector that detects certain biohazard substances. The Company is also a reseller of handheld assays used for detection of five bioterrorism agents, radiation detection systems, and antimicrobial products.
Feb 19, 2009 -- Vital Products, Inc. (OTCBB: VTLP), a multichannel innovator in the industrial packaging sector, announced today that it has signed an agreement to market a paper packaging system.
Vital Products Chief Executive Officer, Michael Levine remarked, "Paper packaging has been a staple in the industrial packaging market for many years. Machines today produce different profiles of scrunched or crumpled paper, but in the end they all perform a similar function."
Mr. Levine further commented, "This new agreement gives us access to a new green technology that stands alone in the market. Quite frankly there is nothing available, or in fact similar to the product that we will be marketing. The system produces a superior kraft paper product that simulates a moldable nest, yet remains price competitive with other paper products, giving us the advantage of performance and range of use."
About Vital Products, Inc.
Vital Products, Inc. is a distributor of industrial packaging products. The company plans to identify and invest in emerging market segments in the industrial packaging sector as well as research and develop products it can patent and license in the environmentally sustainable packaging markets.
About Standoutstocks.com
Standoutstocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies. Standoutstocks.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at www.Standoutstocks.com and select the "join now" button.
Join us at www.standoutstocks.com for a complimentary subscription to the most exciting online financial newsletter on the market.
Disclaimer: Verify all claims and do your own due diligence. Standoutstocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Standoutstocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Standoutstocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Standoutstocks.com is owned and operated by Standoutstocks.com. Neither Standoutstocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Standoutstocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Standoutstocks.com statements and opinions and such statements and opinions cannot be considered independent. Standoutstocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Standoutstocks.com services are often paid for using free-trading shares. Standoutstocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.
Visit us for a full Disclaimer at: www.standoutstocks.com/disclaimer.aspx
CONTACT: Standoutstocks.com e-mail: info@standoutstocks.com WWW: http://www.standoutstocks.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
